Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Aurinia Pharmaceuticals has raised $3.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Aurinia Pharmaceuticals's investors include RA Capital Management, New Enterprise Associates, Redmile Group, Lumira Ventures, Great Point Partners.
Aurinia Pharmaceuticals is headquartered in Victoria, Canada.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Aurinia Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aurinia Pharmaceuticals — Funding & Investors." VCBacked, June 2, 2026, https://www.vcbacked.co/company/aurinia-pharmaceuticals. Accessed November 11, 2026.
VCBacked. (2026). Aurinia Pharmaceuticals — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/aurinia-pharmaceuticals
{{cite web |title=Aurinia Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/aurinia-pharmaceuticals |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Aurinia Pharmaceuticals? Request a listing update